Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LAFTI probiotic line lands at Lallemand

This article was originally published in The Tan Sheet

Executive Summary

Institut Rosell-Lallemand acquires the LAFTI probiotics line from Dutch ingredient giant DSM. The subsidiary of Canadian company Lallemand said March 8 it will expand LAFTI's dietary supplement applications into sports nutrition and recovery. Current LAFTI applications include Attune Foods' Attune Probiotic Wellness Bars (1"The Tan Sheet" April 2, 2007). DSM retains a license to LAFTI's dairy business, consistent with the firm's food- and beverage-based probiotic application strategy, Lallemand said

You may also be interested in...



Brand New Brands Introduces Incubation To Functional Foods Market

Brand New Brands is bringing the incubator business model into the functional foods market with its four spinout companies, which co-founder William Rosenzweig says will continue to be "nurtured" with innovations in product quality

CNS Biomarkers: Monument Targets Schizophrenia, Anxiety And Cognitive Decline

Steven Powell, chair of the board at Cambridge Cognition, talks about the group’s latest spin-off company, Monument Therapeutics.

Novartis Q4 Preview: Launches Likely To Deliver

Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.

Topics

UsernamePublicRestriction

Register

PS103920

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel